# Immunocore Holdings share price today (Immunocore Holdings plc, IMCR)

> Immunocore Holdings plc's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. IMCR · Healthcare · Biotechnology · data as of 5 November 2026. Page: https://www.sectoralpha.in/us/stocks/imcr

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $28.40 (−15.2% in a year)
- Revenue (Jun 2026): $116 M (+18.3% on a year ago)
- Profit (Jun 2026): −$808 K
- Operating margin: −2.6% (+12.6 points on a year ago)

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the Immunocore Holdings share price today? Immunocore Holdings plc's share price was $28.40 at the close on 5 November 2026. That is 10.4% below its average price over the last 200 trading days. In the last 52 weeks it traded between $28 and $40, and at that close it sat 3% of the way up from that low. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 7 weeks running. Over the last 1 year the share price moved −19% while the S&P 500 moved +18%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 18 September 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Immunocore Holdings pay? Immunocore Holdings plc pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Immunocore Holdings on? Immunocore Holdings is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Immunocore Holdings profitable? Immunocore Holdings plc posted a net loss of $808 K in the Jun 2026 quarter. The full FY25 year was a loss of $35.5 M. That loss is 0.7% of the quarter's revenue. The same quarter a year earlier lost $10.3 M. 8 of the last 12 reported quarters were loss-making. ## How much revenue does Immunocore Holdings make, and is it growing? Immunocore Holdings plc reported $116 M of revenue in the Jun 2026 quarter, +18.3% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 4 years it has grown 82.0% a year on average. The last full year, FY25, came in at $400 M. The last four reported quarters add to $431 M. FY25 revenue was $400 M, +29.0% on the year before. Recent pace: the last four quarters grew +21.3% on average, against 82.0% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +21.0%, against +23.8% a year over the last 8 quarters (stabilising). ## How much of every $100 of sales does Immunocore Holdings keep? Immunocore Holdings plc's operating margin was −2.6% in the Jun 2026 quarter, 12.6 percentage points higher than the same quarter a year ago. Across 5 years it has been between −478.7% and −6.4%. The latest quarter is above every full year in that period. Why the margin moved: operating margin changed +12.6 percentage points on the year while gross margin changed +6.8 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Immunocore Holdings' profit turning into cash? Immunocore Holdings plc's cash-flow history is too short to judge how much of its profit turns into cash. In FY25 its operations used $10.7 M of cash, against −$35.5 M of profit. After $4.3 M of spending on assets, free cash was −$15.1 M: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Immunocore Holdings' cash go? Immunocore Holdings plc does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $14.9 M on assets over the last 3 years. Averaged over those years that is 1.2% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $14.9 M over the last 3 years. In short: most of the cash goes on covering the loss, not on new assets; spending on assets is small next to it. ## What is Immunocore Holdings' P/E ratio, and how does it compare with its own history? Immunocore Holdings plc has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values Immunocore Holdings plc at 3.7× its FY25 revenue of $400 M. The P/E comes back here once profit turns positive. ## Is the Immunocore Holdings business getting better or worse? Immunocore Holdings plc's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Immunocore Holdings earn on its capital? Immunocore Holdings plc earned a ROE of −9% in FY25. That is up from a low of −78% in FY21. Its return on capital used (ROIC) is left out: on sales this small it reads −10,498%, a number that says nothing useful about the business. It comes from a −8.9% net margin and 0.37× asset turnover (sales divided by assets). Why the return is what it is (FY25): a −8.9% net margin × 0.37× asset turnover × 2.80× leverage (assets divided by equity) ≈ −9.2% on equity. The margin does its share; borrowing is a big part of it. ## Does Immunocore Holdings have too much debt? Immunocore Holdings plc has total debt of $435 M against shareholder equity of $420 M as of Jun 2026, so its debt is 1.04× its equity. Year by year, that ratio went from 0.37 in FY21 to 1.15 in FY25. Keep that borrowing in mind when reading the returns on this page. ## What is the Immunocore Holdings shareholding pattern? We have no ownership or short-position figures for Immunocore Holdings plc, so this section says so rather than fill the gap. At normal trading volumes, closing those positions would take about 17.1 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. ## How far is Immunocore Holdings from balance-sheet trouble? For Immunocore Holdings plc, the Z-score is 1.65. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the danger zone. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 1.65 is inside the danger zone, so the balance sheet is a real risk. ## How does Immunocore Holdings rank in its industry? There is no score against its industry: Immunocore Holdings plc is not among the largest members shown in this industry comparison for Biotechnology. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Immunocore Holdings compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Immunocore Holdings in size? Immunocore Holdings is the 94th largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 5 November 2026). Just above it: Intellia Therapeutics, Inc., Precigen, Inc. and Nuvation Bio Inc. Just below it: uniQure N.V., Ascentage Pharma Group International and Ocular Therapeutix, Inc. ### Biotechnology companies close in size

1. [Intellia Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/ntla) $1.6 billion
2. [Precigen, Inc.](https://www.sectoralpha.in/us/stocks/pgen) $1.5 billion
3. [Nuvation Bio Inc.](https://www.sectoralpha.in/us/stocks/nuvb) $1.5 billion
4. Immunocore Holdings plc $1.5 billion
5. [uniQure N.V.](https://www.sectoralpha.in/us/stocks/qure) $1.5 billion
6. [Ascentage Pharma Group International](https://www.sectoralpha.in/us/stocks/aapg) $1.4 billion
7. [Ocular Therapeutix, Inc.](https://www.sectoralpha.in/us/stocks/ocul) $1.4 billion

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [Amalgamated Financial Corp.](https://www.sectoralpha.in/us/stocks/amal) $1.5 billion · Banks - Regional
2. [Flowers Foods, Inc.](https://www.sectoralpha.in/us/stocks/flo) $1.5 billion · Packaged Foods
3. Immunocore Holdings plc $1.5 billion
4. [EverCommerce Inc.](https://www.sectoralpha.in/us/stocks/evcm) $1.5 billion · Software - Application
5. [Esquire Financial Holdings, Inc.](https://www.sectoralpha.in/us/stocks/esq) $1.5 billion · Banks - Regional

## What else do people ask about Immunocore Holdings? ### What were Immunocore Holdings's latest quarterly results? Immunocore Holdings plc reported revenue of $116 M and a net loss of $808 K for the Jun 2026 quarter. Earnings per share were −$0.02. The operating margin was −2.6%, 12.6 percentage points higher than a year earlier (as of 5 November 2026). ### What is Immunocore Holdings's market cap? Immunocore Holdings plc's market capitalisation is $1.5 B at a stock price of $28.40. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 5 November 2026). ### How is Immunocore Holdings performing? Immunocore Holdings plc's latest readings are below. Over the past 13 weeks it has done worse than the S&P 500, for 7 weeks running. This describes what the data did, not a rating (as of 5 November 2026). ### Will Immunocore Holdings's stock price go up? This page does not forecast Immunocore Holdings plc's stock price. What it shows instead: the stock price is $28.40. Nobody can reliably say which way a price will move, and this site does not try (as of 5 November 2026). ### Where is Immunocore Holdings in its business cycle? Immunocore Holdings plc's FY25 operating margin was −6.4%, against a 5-year range of −478.7% to −6.4%: the middle of its own range, neither a peak nor a low. The latest quarter was −2.6%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 5 November 2026). ### What could break the Immunocore Holdings story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 5 November 2026). ### Is Immunocore Holdings a stock worth studying right now? What the numbers show: Immunocore Holdings plc's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 5 November 2026). This is research, not advice. We’re not SEBI-registered.